Applications of PET in Diagnosis and Prognosis of Leukemia

Zixuan Zhao, MB1, Yanwen Hu, MB1, Jihui Li, MB1, Yeye Zhou, MB1, Bin Zhang, PhD1, and Shengming Deng, MD1

Abstract
As a malignant hematopoietic stem cell disease, leukemia remains life-threatening due to its increasing incidence rate and mortality rate. Therefore, its early diagnosis and treatment play a very important role. In the present work, we systematically reviewed the current applications and future directions of positron emission tomography (PET) in patients with leukemia, especially 18F-FDG PET/CT. As a useful imaging approach, PET significantly contributes to the diagnosis and treatment of different types of leukemia, especially in the evaluation of extramedullary infiltration, monitoring of leukemia relapse, detection of Richter’s transformation (RT), and assessment of the inflammatory activity associated with acute graft versus host disease. Future investigations should be focused on the potential of PET/CT in the prediction of clinical outcomes in patients with leukemia and the utility of novel radiotracers.

Keywords
PET, FDG, leukemia, diagnosis, prognosis, extramedullary

Received: June 17, 2020; Revised: July 29, 2020; Accepted: August 6, 2020.

Introduction
As a type of malignant clonal disease, leukemia originates from hematopoietic stem cells. A large number of cloned leukemia cells proliferate and accumulate in bone marrow and other hematopoietic tissues, leading to inhibited normal hematopoietic function and infiltration of other non-hematopoietic tissues and organs. According to the differentiation and maturity of leukemia cells and the natural course of the disease, leukemia can be broadly classified into 4 main types as follows: acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), chronic lymphoblastic leukemia (CLL) and chronic myeloblastic leukemia (CML). CLL is the most common form in elderly patients, and ALL is the most common form in pediatric patients. Other rare types include hairy cell leukemia (HCL), acute promyelocytic leukemia (APML) and T-cell prolymphocytic leukemia (T-PLL).1 Acute leukemia (AL) has become a public health concern due to its increasing incidence rate and mortality rate. Therefore, its early diagnosis and treatment greatly contribute to the prognosis of leukemia patients.

Positron emission tomography (PET) is widely applied as a molecular imaging approach, in which radiopharmaceuticals are used as tracers to graphically display the metabolism of the whole body and focal lesions to diagnose diseases. PET scans are now routinely combined with computed tomography (PET/CT) or magnetic resonance imaging (PET/MRI). The functional metabolic imaging of PET is fused with anatomical structure imaging of CT or MRI, which can not only obtain information, such as function and metabolism, but also have high spatial resolution and accuracy. Moreover, a variety of PET radiotracers have been introduced.

As the most common PET radiotracer, 18-fluorodeoxyglucose (18F-FDG) is a radio-labeled glucose analog, which can reflect the increased level of glucose consumption. The malignant tumors often have a significantly higher level of 18F-FDG uptake because of high glucose uptake and accelerated glucose metabolism.2,3,18F-FDG can also accumulate under a variety of benign and physiological conditions, leading to false-positive interpretation. In general, the 18F-FDG uptake in the benign disease and physiological conditions remains low.4,5

18F-FDG PET/CT has been widely used as a new non-invasive molecular imaging technique in diagnosing, staging,
restaging and response assessment of hematologic malignan-
cies, such as lymphoma, 6,7 myeloid sarcoma 8 and multiple
myeloma. 9 In recent years, more and more research reports
have shown that 18F-FDG PET/CT also plays an important role
in the diagnosis and treatment of different types of leukemia,
especially AL. 10 In the present work, we systematically
reviewed the current applications and future directions of PET
in leukemia patients, especially 18F-FDG PET/CT.

1. The utility of 18F-FDG PET/CT in the diagnosis of leukemia

18F-FDG PET/CT is not routinely used in the assessment of
leukemia, because typical leukemia does not present with a
solid tumor, and bone marrow (BM) examination remains the
gold standard test of its diagnosis.

Increased uptake of 18F-FDG in BM may be a characteristic
finding in leukemia patients, including diffuse and focal pat-
tterns. Alam et al. 3 have revealed that 18F-FDG super BM
uptake is a highly potent indicator for the BM malignant infil-
tration, which mostly originates from lymphoma and leukemia.
Arimoto et al. 11 have shown that all 9 leukemia patients have
increased BM uptake of 18F-FDG on PET/CT in the vertebrae,
pelvis, sternum, ribs and extremities, reflecting the increased
number and elevated metabolic activity of leukemic cells in the
BM. Furthermore, some patients have focal or inhomogeneous
BM uptake of 18F-FDG, especially in the extremities. This may
reflect the focal bone localization of leukemia or focal sites
with the decreased number and reduced activity of leukemic
cells due to BM necrosis. In addition, increased focal uptake of
18F-FDG in BM can detect focal bone localization of leukemia,
especially in patients with relapsed leukemia. 12

18F-FDG PET/CT may become a critical diagnostic tool for
the early diagnosis of leukemia in patients without a remark-
able abnormality in peripheral blood or patients presenting with
non-specific symptoms, such as bone pain and fever. Arslan
et al. 13 have reported an ALL patient presenting with fever of
unknown origin, who is diagnosed after 18F-FDG PET/CT
showing diffuse BM involvement. Ennishi et al. 14 have
reported a patient with a long-term fever and diffuse bone pain.
Routine hematologic and radiologic (CT and MRI) investiga-
tions do not reveal any abnormalities. 18F-FDG PET/CT shows
an increased diffuse BM uptake, and the BM biopsy reveals
98% lymphoblasts. Therefore, 18F-FDG PET/CT may be a use-
ful tool for the non-invasive assessment of patients with sus-
pected leukemia.

However, there are some limitations when 18F-FDG PET/
CT is used in the diagnosis of leukemia. The increased BM
uptake is not specific for leukemia, which can also be observed
in the patients with infections and those treated with granulo-
cyte colony-stimulating factor (GCSF) or erythropoietin
(EPO). 15,16 In these situations, it is difficult to distinguish
whether such elevation is caused by malignant disease or
inflammatory response, although some articles have reported
that BM malignant infiltration derived from lymphoma and
leukemia generally has a markedly higher 18F-FDG uptake in
the BM compared with benign etiologies. 3,17 Li et al. 18 have
developed a 18F-FDG PET/CT radiomic analysis with machine
learning model for the patients with suspicious relapsed AL,
and found that high-dimensional, high-throughput radiomic
features provide an objective and efficient mechanism for iden-
tifying the BM involvement, and it can complement the visual
analysis to derive a more comprehensive, confident and accu-
deate diagnosis.

The Utility of 18F-FDG PET/CT in
Extramedullary AL

Clinical Features of Extramedullary Involvement of AL

Leukemia usually originates from the BM with the typical
symptoms of inhibited hematopoietic function, such as anemia,
blooding and fever. Extramedullary AL refers to lesions that
occur in any anatomical sites outside BM, and it is common in
monocytic and myelomonocytic leukemia. Granulocytic sar-
coma (GS) (also known as myeloid sarcoma or chloroma) is a
rare extramedullary manifestation, which is commonly found
in patients with AML but uncommonly found in myelodysplas-
tic syndrome, CML or myeloproliferative disorders, and GS
can precede the diagnosis or occur during relapse after initial
treatment 19,20. Most previous studies have reported that the
prevalence of extramedullary AL remains below 10%. 19,21
However, some recent studies have shown that up to 30%
of AML patients are accompanied by extramedullary involve-
ment, 22 and such situation has been increasingly reported in
ALL patients. 23 Extramedullary AML is most frequently
located in the skin, while it can affect almost every part of the
body. 24,25 Moreover, some studies have found that testis and
kidney involvement are only seen in the ALL patients. 26,27

Detection of Extramedullary AL

Extramedullary infiltration of AL is not easily diagnosed, espe-
циально in the recurrent AL patients, because it often grows
slowly and its clinical symptoms and laboratory tests are usu-
ally not abnormal. Patients are often diagnosed until they have
intolerable symptoms, extramedullary lesions are often large or
widespread, and outcomes are poor by this time. The difficult
cure of leukemia and its high mortality can be largely attributed
to the existence of these extramedullary lesions. Therefore, the
extramedullary infiltration should be detected and identified as
early as possible.

Although traditional imaging modalities, such as CT, MRI
and ultrasound, have been widely used for the detection of
extramedullary involvement, they have limitations since the
sensitivity of these approaches is not high enough to detect the
small lesions and occult lesions, and they cannot provide a
panoramic picture of the whole body. Some articles have shown
that 18F-FDG PET/CT may be a useful tool in detecting
extramedullary AML and guiding biopsies.

Aschoff et al. 28 have compared the results of CT alone or
PET alone with 18F-FDG PET/CT in 10 GS patients. The study
shows that the combination of PET and CT avoids 5 false-
positive manifestations compared with PET alone, as well as 13 false-negative and 1 false-positive compared with CT alone. Cribe et al.22 have reported that 18F-FDG PET/CT can reveal more than twice as many patients with extramedullary AL than found by clinical examination, and the responses of extramedullary AL detected by 18F-FDG PET/CT are concordant with the BM responses assessed by pathology examination. Zhou et al.26 have also shown that 18F-FDG PET/CT is a sensitive imaging modality (93.3%) for the detection of extramedullary AL with the intense 18F-FDG uptake of the lesions (Figure 1).

**Monitoring of Extramedullary Relapse**

Leukemia relapse refers to the reappearance of leukemia cells in the peripheral blood, or the extramedullary invasion of leukemia cells, which occurs within 2 years after complete remission. It can occur intramedullary or extramedullary, or both, and intramedullary relapse is more frequently detected. Despite the high rates of initial complete remission in AL, relapse remains a major cause of failure in treatment.29 In the past, retrospective data have indicated that the rate of extramedullary relapse alone is only 0.65% in AML patients after allogeneic hematopoietic stem cell transplantation (HSCT) compared with 30% in those with combined BM and extramedullary disease.30 However, it has been reported that the incidence of extramedullary relapse is increasing, especially in the patients who have received HSCT.31,32 One study has shown that up to 20% of AML patients have extramedullary relapse after HSCT, and ALL patients have a higher recurrence rate.33 Intramedullary relapse can often easily be diagnosed by BM biopsy and blood cell examination. However, it is difficult to detect extramedullary relapse. Some articles have indicated that FDG-PET/CT can be helpful for detecting extramedullary relapse.23,34,35 FDG-PET/CT is sensitive in determining the location and metabolic activity of recurrent malignant tumors compared with other imaging modalities, and it can be helpful in managing individualized treatment of patients. Tan et al.36 have reported that a 16-year-old girl, who is diagnosed as ALL

---

**Figure 1.** 18FDG-PET/CT images demonstrating extramedullary AL. (A) A 21-year-old male received allo-HSCT for ALL. 18FDG-PET/CT images revealed right pleura with diffuse intense 18F-FDG uptake, which was proved to be extramedullary AL by biopsy. (B) A 20-year-old male received allo-HSCT for ALL. 18FDG-PET/CT images showed bilateral kidneys, muscle, and subcutaneous tissue were involved by extramedullary AL (Reference: Zhou WL, et al.26).
and achieves complete remission after allo-HSCT 9 years ago, is presented with a mass in the left eye through a normal visual inspection. FDG PET/CT imaging has found increased FDG uptake in an oval mass in the soft tissue between the left eyeball and the left nasal. The extramedullary relapse is confirmed by biopsy, while the BM aspiration biopsy is negative. Stolzel et al.37 have performed PET/CT for 10 patients with de novo and relapsed AML and histologically proven extramedullary disease. The scans detect the known extramedullary lesions in 9 out of 10 patients (90%). Furthermore, additional extramedullary sites are detected in 6 patients (60%). It is possible to identify known and clinically undetectable extramedullary manifestations of AML by using PET/CT.

Since most of these patients relapse within a short period of time after initiation of therapy or have refractory disease, using 18F-FDG PET/CT to detect extramedullary disease has an important impact on treatment decisions and outcomes. In order to obtain a higher survival rate and a better prognosis, more and more clinical attention has been paid to the occurrence and detection of extramedullary involvement of AL.

**Staging and Response Assessment of Leukemia**

18F-FDG PET/CT has been widely used in staging, restaging and response assessment of lymphoma. Likewise, for AL patients, PET/CT can also help determine the extent of the disease and assess the therapy response. It has been determined in a study consisting of 124 AL patients by Cunningham et al.38 The whole body 18F-FDG PET/CT imaging before and after treatment can evaluate whether the treatment is effective by a comparison. Rao et al.39 have reported a case of a 64-year-old man who is diagnosed with AML and subsequently has recurrent extramedullary relapses. Doma et al.40 have reported a case of a 66-year-old man diagnosed with HCL, who has an extensive pathological retroperitoneal mass and infiltration of the spleen and skeletal involvement which are highly avid on 18F-FDG PET/CT. In addition, all previous pathological sites show normal FDG uptake on 18F-FDG PET/CT after treatment. These cases demonstrate the usefulness of FDG-PET for staging and assessment of the treatment response.

Moreover, 18F-FDG PET/CT may be useful in children for relapsed/refractory leukemia. A study has reported 2 children with AML who undergo PET/CT at diagnosis as well as in remission and detected 5 extramedullary disease lesions, only 2 of which are detectable on clinical examination.41 Kaya et al.42 have found that 18F-FDG PET/CT may be a complementary imaging modality to improve the detection of subtle leukemic infiltration in children with suspected leukemia progression or recurrence after chemotherapy or allo-SCT. Four patients who have undergone allo-HSCT are observed with increased multifocal BM uptake and extramedullary leukemia on 18F-FDG PET/CT, while they show negative BM biopsies. Focal BM involvement may be missed by BM biopsy alone, while 18F-FDG PET/CT-guided targeted biopsies may overcome such problem in these patients.

**The Utility of 18F-FDG PET/CT in Patients With CLL and Richter’s Syndrome (RS)**

CLL is the most common type of leukemia in Western countries.43 It is generally an indolent and low-grade lymphoproliferative disease.44 RS or Richter’s transformation (RT) refers to the development of CLL to another more aggressive lymphoma or lymphoid malignancy, most commonly to diffuse large B-cell lymphoma (DLBCL).45 Transformations into PLL, Hodgkin disease and small non-cleaved cell lymphoma have also been documented.46,47 The syndrome is first described by Richter MN in 1928, who has reported a patient with CLL transformed into fatal rapidly progressing generalized lymphadenopathy and hepatosplenomegaly.48 RS is one of the main complications of CLL, which occurs in about 2.2-8% of CLL patients. RS may represent the end stage of CLL. The prognosis is poor, and the median survival duration ranges from 5 months to 8 months.49
Therefore, prompt diagnosis is necessary. However, the clinical features of RS are non-specific, such as fever, progressively enlarging lymph nodes and suggestive lab findings of elevated lactate dehydrogenase (LDH) and β-2 microglobulin levels. Previous reports have shown that high-dose $^{67}$Ga scanning can detect RT. However, it cannot be a routine imaging test for lymphoma due to some restrictions. Conventional imaging, such as CT, can be used to evaluate lymphomatous lesions with compressive or infiltrative patterns. In the case reported by Mota et al., the CT scan can detect an ocular lymphoma with RS. Papajik et al. have reported the case that there is no advantage in performing $^{18}$F-FDG PET/CT over CT as a surveillance tool in CLL patients, while if RS is suspected, an $^{18}$F-FDG PET/CT can be extremely beneficial in confirming the diagnosis. $^{18}$F-FDG PET/CT can detect RT of CLL to large cell lymphoma with a high sensitivity, specificity and negative

Figure 3. $^{18}$FDG-PET/CT images demonstrating GVHD. A 46-year-old patient who presented with signs of acute GI-GVHD 30 days after allo-SCT. $^{18}$F-FDG PET/CT which performed at 25 days after allo-HSCT showed colon FDG uptake increased. (Reference: Bodet-Milin C, et al.69).
Table 1. PET Radio Tracers in Leukemia as well as Their Main Advantages and Disadvantages.

| PET radiotracers | Advantages                                                                 | Disadvantages                                                                 |
|------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| $^{18}$F-FDG     | $^{18}$F-FDG can detect various hematologic neoplasms due to altered glucose consumption. Its half-life is appropriate for clinical use and it is inexpensive to manufacture reliably. | Sometimes it is difficult to distinguish benign lesions such as inflammation from malignant disease. And it may not be able to detect malignant involvement in areas of high glucose metabolism such as the meninges or the pericardium. |
| $^{18}$F-FLT     | $^{18}$F-FLT PET may reduce the false-positive manifestations due to infection or inflammation, and it may be appropriate for the detection of meningeal diseases because of the negligible background uptake in the brain and skull. | $^{18}$F-FLT uptake in bone marrow is unable to demonstrate leukemia infiltration due to it may be caused by both neoplastic and normal hematopoietic cells. |
| $^{68}$Ga-Pentixafor | $^{68}$Ga-Pentixafor may possibly be useful for detection, characterization, and treatment response assessment in CLL patients. | $^{68}$Ga-Pentixafor reflects the CXCR4 expression, and only used in CXCR4-based CLL. |
| $^{11}$C-choline | The negligible uptake of $^{11}$C-Choline in the normal brain may be helpful for the diagnosis of extramedullary AL in brain. | $^{11}$C-Choline was inappropriate for routine clinical use because of the rapid in vivo degradation and short half-life of $^{11}$C. |

Predictive value. Earlier studies have reported a low degree of $^{18}$F-FDG avidity of PET in patients with CLL or small lymphocytic lymphoma (SLL), which is likely attributed to the lower mitotic activity and glucose consumption of lymphocytes. Conversely, a high level of $^{18}$F-FDG accumulation has been observed in RS patients. Bruzzi et al. have shown that the abnormal increase in the standardized uptake value (SUV) of $^{18}$F-FDG raises the suspicion for RS, especially if SUV$_{\text{max}} \geq 5.0$, and should be considered highly suggestive of histological transformation. The overall sensitivity and specificity of $^{18}$F-FDG PET/CT for RS have been reported to be 91% and 80%, respectively. Michallet et al. have reported that an SUV$_{\text{max}} > 10$ seems to be the optimal threshold for distinguishing RS in CLL, and such threshold is also strongly correlated with mortality. In addition, diagnosis of RS is confirmed by biopsy of an enlarging lymph node or other involved sites (Figure 2). Furthermore, for patients suspected of having RS, $^{18}$F-FDG PET/CT can also identify sites of increased $^{18}$F-FDG uptake as intensely metabolically active nodes to guide biopsy or surveillance. Sood et al. have presented a case of CLL with suggestive clinical features of RS. $^{18}$F-FDG PET/CT shows liver and lung involvement with no lymphadenopathy, which is an unusual presentation of RS.

In addition, the role of $^{18}$F-FDG PET/CT in identifying RS in the era of novel agent CLL therapy has evolved in recent years. Wang et al. have found that CLL patients receiving B-cell receptor pathway inhibitor (BCRI) therapy should undergo $^{18}$F-FDG PET/CT for the evaluation of potential disease progression. A biopsy should be considered in patients with suspected RS when an SUV$_{\text{max}} \geq 5$.

The Utility of $^{18}$F-FDG PET/CT in Graft Versus Host Disease (GVHD) After Allo-HSCT

HSCT has been proved to be an important method for a variety of life-threatening malignancies, and it may be the only cure for most malignant blood diseases. However, HSCT is limited by the immunological recognition and destruction of host tissues, which is termed as GVHD. As one of the most serious complications, GVHD is the primary cause of non-recurrence death in patients after allo-HSCT but rare in those after autologous HSCT. GVHD affects 50–70% of patients receiving allo-HSCT. One remarkable feature of GVHD is its predilection for certain organ systems, such as the epithelial surfaces of the skin and mucous membranes, the crypts of the gastrointestinal tract, and the biliary ducts of the liver. About 80% of patients with acute GVHD have skin involvement, and more than 50% have gastrointestinal GVHD. Severe acute gastrointestinal tract (GIT)-GVHD is likely the most serious manifestation, and it is a major determinant of long-term survival.

Although clinical investigation, laboratory tests, and histology usually lead to an early diagnosis of skin or liver GVHD, GIT-GVHD can be difficult to diagnose because of its non-specific clinical symptoms, such as anorexia, nausea, vomiting, watery diarrhea, intestinal bleeding, abdominal pain, and ileus. Endoscopic examination and histology are mainly used to exclude differential diagnosis, and this method remains unsatisfactory in most cases. Furthermore, only the evolution of acute GIT-GVHD during the initial weeks will ultimately define the severity of GVHD. Non-invasive tests for assessment of GVHD activity are desirable but lacking. Some studies have indicated that $^{18}$F-FDG PET/CT may be a sensitive and specific non-invasive technique to assess the inflammatory activity associated with acute GIT-GVHD.

Stelljes et al. have observed 30 patients with suspected intestinal GVHD beyond 20 days after transplantation. Of the 17 histologically diagnosed patients, 14 patients show significant intestinal FDG uptake, mainly in the colon. Of the 13 patients without histological evidence, there is no increased FDG uptake. It shows for the first time that $^{18}$F-FDG PET/CT can be used as a sensitive and specific non-invasive method to diagnose and map the inflammatory component of intestinal
| Number          | Title of clinical trials                                                                 | Outcome Measures                                                                 | Status; Study Results                                                                 |
|-----------------|------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| NCT03422731     | Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy | - Change over time in cellularity and adiposity                                   | - Recruiting                                                                       |
|                 |                                                                                         | - Change over time of red marrow (cellularity) and yellow marrow (adipocyte)      | - Start: February 6, 2018                                                           |
|                 |                                                                                         | - Number of hematopoietic stem cell (HSC) colony forming units (subanalysis)      | - Completion: February 6, 2023                                                      |
|                 |                                                                                         | - Ratio of HSC subpopulations (sub-analysis) Hematopoietic stem cell density in bone marrow biopsy samples (subanalysis) |                                                                                  |
|                 |                                                                                         | - Microvascular density in bone marrow biopsy samples (sub-analysis)              |                                                                                  |
|                 |                                                                                         | - Standardized uptake value (SUV) distribution at different skeletal sites        |                                                                                  |
|                 |                                                                                         | - SUV distribution and presence of focal hot spot                                 |                                                                                  |
|                 |                                                                                         | - Change in FLT PET activity                                                     |                                                                                  |
|                 |                                                                                         | - SUV max at site of biopsy                                                      |                                                                                  |
| NCT02682732     | Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia              | - Number of patients with heterogeneous PET/CT activity before induction chemotherapy | - Recruiting                                                                        |
|                 |                                                                                         | - Number of patients with residual PET/CT activity following induction chemotherapy | - Start: April 2016                                                               |
| NCT02390635     | PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia | - Incidence of extramedullary myeloid leukemia (EML)                              | - Completion: December 2020                                                        |
|                 |                                                                                         |                                                                                  | - No clinical data published                                                        |
| NCT02392429     | FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia | - Negative predictive value of post-treatment FLT PET/CT imaging for CR in comparison with blast counts from bone marrow biopsy (BMBX) | - Recruiting                                                                        |
|                 |                                                                                         | - PPV of post-treatment FLT PET/CT imaging for complete remission                | - Start: May 2, 2016                                                              |
|                 |                                                                                         | - Sensitivity of FLT PET/CT for complete remission detection                      | - Completion: May 31, 2021                                                         |
|                 |                                                                                         | - Specificity of FLT PET/CT for complete remission detection                      | - No clinical data published                                                       |
|                 |                                                                                         | - Pre-treatment FLT PET/CT activity as a predictor of complete remission         |                                                                                  |
|                 |                                                                                         | - Change between retreatment and posttreatment FLT PET/CT activity as a predictor of complete remission |                                                                                  |
|                 |                                                                                         | - Biologic correlates of AML(MRD assessment)                                     |                                                                                  |
| NCT02103530     | Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT | - Value of FLT PET/CT in early response assessment of induction chemotherapy in acute myeloid leukemia | - Completed                                                                         |
|                 |                                                                                         |                                                                                  | - Start: April 2014                                                               |
|                 |                                                                                         |                                                                                  | - Completion: December 2015                                                       |
| NCT01599429     | Study of the Predictive Marker FLT in Patients Suffering From AML                          | - To measure the prognostic value of metabolic activity in the bone marrow with FLT-PET prior to chemotherapy in patients with AML disease. | - Unknown status                                                                  |
|                 |                                                                                         |                                                                                  | - Study: October 2011                                                             |
|                 |                                                                                         |                                                                                  | - Completion: October 2015                                                        |
|                 |                                                                                         |                                                                                  | - No clinical data published                                                      |
| Number     | Title of clinical trials                                                                 | Outcome Measures                                                                 | Status; Study Results                                                                 |
|------------|-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| NCT01964625 | Positron Emission Tomography-Computed Tomography (PETCT) Scanning in Chronic Graft Versus Host Disease (cGvHD) | - To determine ability of PET-CT scans to delineate and stage initial chronic GvHD [Time Frame: At initial diagnosis of chronic GvHD]  
- To determine ability of PET-CT scans to document response to chronic GvHD therapy [Time Frame: PET-CT performed ≤ 6 months from study PET-CT #1] | Terminated  
- Start: November 2010  
- Completion: August 2013  
- No clinical data published |
| NCT01596192 | PETCT for Diagnosing and Monitoring Acute GVHD                                             | - Change of gut FDG uptake at onset and after treatment with steroids in patients with acute GVHD  
- Correlation between blood cytokines level and PETCT results | Unknown status  
- Start: May 2012  
- Completion: June 2013  
- No clinical data published |
| NCT02352064 | Evaluation of the Diagnostic Value of PET (18F-FDG) in Chronic Graft Versus Host Disease (cGVH) | - Measure of sensibility and specificity of PET (18FFDG) for cGVH diagnosis in comparison to standard care | Unknown status  
- Start: January 2015  
- Completion: January 2018  
- No clinical data published |
| NCT03546556 | 18-FLT PET/MR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant Patients | - Overall FLT-PET Bone Marrow Signal  
- Overall FLT-PET Signal Intensity within Host Secondary Lymphoid Sites  
- Overall Long-Term FLT-PET Bone Marrow Signal  
- Overall Long-Term FLT-PET Signal Intensity within Host Secondary Lymphoid Sites  
- Differences in FLT Uptake in Autologous HSCT and Allogeneic HSCT Patients  
- Strength of FLT-PET Signal and Transfusion Independence  
- Strength of the FLT-PET Signal and Bone Marrow Cellularity  
- Strength of FLT-PET Signal and Transfusion Independence (Long Term)  
- Strength of FLT-PET Signal and Bone Marrow Cellularity (Long Term)  
- Isolated/Asymmetric Foci of Increased FLT  
- Strength of FLT-PET signal and MRI Findings  
- Overall FLT-PET Signal Intensity and Acute Graft Versus Host Disease | Recruiting  
- Start: January 1, 2017  
- Completion: June 2021  
- No clinical data published |
| NCT03367962 | Detection of Graft Versus Host Disease With [18F]F-AraG                                    | - Severity/score of aGVHD  
- Development of aGVHD  
- Healthy subject | Recruiting  
- Start: May 15, 2018  
- Completion: December 2020  
- No clinical data published |

*Clinical trials which currently display an entry in www.clinicaltrials.gov.uk
GVHD, and monitor the treatment response of intestinal GVHD in patients after allo-HSCT (Figure 3). A prospective study by Bodet-Milin et al.\(^6\) has found that 9 of 10 (90\%) patients with proven acute GIT-GVHD have a positive \(^{18}\)F-FDG PET/CT, including 5 patients before developing clinical symptoms, suggesting that this imaging technique would be potentially useful for early the diagnosis of acute GVHD in some cases. Dejanovic et al.\(^7\) have reported that a patient with extensive and multifocal involvement of the GIT in the whole body \(^{18}\)F-FDG PET/CT develops severe acute GVHD at 93 days post allo-SCT, demonstrating that \(^{18}\)F-FDG PET/CT can be valuable in mapping the activity and distribution of intestinal GVHD and directing targeted biopsies of involved regions.

The Utility of PET With Other Radio Tracers in Leukemia

\(^{18}\)F-Fluordeoxythymidine (\(^{18}\)F-FLT)

\(^{18}\)F-FLT is a thymidine analog that is resistant to in vivo degradation and accumulates predominantly in proliferating tissues. Some studies have reported that \(^{18}\)F-FLT, as a tracer of PET, is able to visualize extramedullary manifestation sites of AML and reflect the disease activity. Compared with \(^{18}\)F-FDG, \(^{18}\)F-FLT PET may reduce the false-positive manifestations due to infection or inflammation, and it may be appropriate for the detection of meningeal diseases because of the negligible background uptake in the brain and skull. This approach may be used in future studies of extramedullary AL.\(^10\),\(^71\)

\(^{68}\)Ga-Pentixafor

\(^{68}\)Ga-Pentixafor is a novel PET radiotracer, which reflects the CXCR4 expression. Initially, a study by Herhaus et al. has demonstrated that in vivo application of \(^{68}\)Ga-Pentixafor PET is feasible in AML.\(^72\) Some researchers have found that \(^{68}\)Ga-Pentixafor uptake is elevated in BM of CLL patients compared with other oncological patients without BM infiltration.\(^68\)Ga-Pentixafor uptake may possibly play a role as an independent parameter for detection and treatment response assessment in CLL patients.\(^1,73\)

\(^{11}\)C-Choline

\(^{11}\)C-Choline PET has been introduced for imaging various tumors, including prostate cancer, lung cancer and brain tumor.\(^74\) The negligible uptake of \(^{11}\)C-choline in the normal brain may be helpful for the diagnosis of extramedullary AL in brain. Qin et al.\(^75\) have reported a case of a 26-year-old man whose brain MRI suggests possible brain metastases, and AML is diagnosed after BM biopsy. The brain lesions are revealed by \(^{11}\)C-choline PET/CT obviously, while the FDG uptake level of brain lesions is similar to adjacent brain in \(^{18}\)F-FDG PET/CT.

In addition, novel targeted tracers for PET may have the potential to further improve the GVHD diagnosis and provide new insights into the mechanisms underlying the pathogenesis and management of intestinal GVHD.\(^76\),\(^78\) A summary table of PET radiotracers in leukemia as well as their main advantages and disadvantages can be seen in Table 1.

Conclusions

In summary, PET has many important applications in leukemia patients, especially \(^{18}\)F-FDG PET/CT. \(^{18}\)F-FDG PET/CT can be useful in diagnosing leukemia, mainly in patients with fever and anemia of unknown origin. Moreover, it is of great value for detecting extramedullary disease, monitoring extramedullary relapse and evaluating treatment response. \(^{18}\)F-FDG PET/CT plays an important role in the early detection of RS and guiding biopsy, in which an \(\text{SUV}_{\text{max}} > 10\) may be the optimal threshold for distinguishing RS in CLL. Furthermore, it can also be used to diagnose GVHD after allo-HSCT. Some novel radiopharmaceuticals for PET also have potential to be used in clinical practice to detect and assess the prognosis of leukemia.

PET may have great potential in the prediction of clinical outcomes in leukemia patients, and it deserves further research. In recent years, PET/MRI has also been increasingly used in clinical practice and shown important value in better visualization of BM without exposure to radiation. It may play more roles in the diagnosis and treatment of leukemia in the future. However, the studies about the use of PET in leukemia are still rare. We found that only few clinical trials are related to the application of PET in the diagnosis and treatment of leukemia, including \(^{18}\)F-FDG PET/CT, PET/MRT and FLT PET in AML and in detecting GVHD, and most of them have no clinical data published (Table 2). Moreover, the sample size of the studies is not large enough so far, which can probably be related to the limitation of PET in the diagnosis of leukemia. Therefore, more trials should be designed, and prospective studies with larger sample size are needed in the future. For example, we can assess the use of \(^{18}\)F-FDG PET/CT to predict the clinical outcome in AL patients treated with allo-HSCT and the use of \(^{18}\)F-FDG PET/CT radiomic analysis in leukemia.

Authors’ Note

Zixuan Zhao and Yanwen Hu contributed equally to this article as the co-first author. Our study did not require an ethical board approval because it did not contain human or animal trials.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Medical Youth Talent Project of Jiangsu Province (No. QNRC2016749) and Suzhou People’s Livelihood Science and Technology Project (SYS2019038).

ORCID iD

Zixuan Zhao https://orcid.org/0000-0003-3990-7809
sarcoma. Initial results. Nuklear Medizin. 2009;48(5):185-191. doi:10.3413/nukmed-0236
29. de Lima M, Porter DL, Battiwalla M, et al. Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part iii. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014;20(1):4-13. doi:10.1016/j.bbmt.2013.08.012
30. Mortimer J, Blinder MA, Schulman S, et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol. 1989;7(1):50-57. doi:10.1200/JCO.1989.7.1.50
31. Lee KH, Lee JH, Choi SJ, et al. Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant. 2003;32(8):835-842. doi:10.1038/sj.bmt.1704223
32. Lee KH, Lee JH, Kim S, Lee JS, Kim SH, Kim WK. High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2000;26(2):147-152. doi:10.1038/sj.bmt.1702488
33. Yoo SW, Chung EJ, Kim SY, et al. Multiple extramedullary relapses without bone marrow involvement after second allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Pediatric Transplant. 2012;16(4):E125-E129. doi:10.1111/j.1399-3046.2011.01546.x
34. Elojeimy S, Stanescu AL, Parisi MT. Use of 18F-FDG PET-CT in pediatric lymph-node acute lymphoblastic leukemia involvement. Nucl Med. 2016;41(3):E137-E140. doi:10.1097/RLU.0000000000000099
35. Cistaro A, Saglio F, Asaftei S, Piercarlo F, Massimo B, Franca F. The role of 18F-FDG PET/CT in pediatric lymph-node acute lymphoblastic leukemia involvement. Radiol Case Rep. 2011;6(4):503. doi:10.2484/rcr.v6i4.503
36. Tan G, Aslan A, Tazeler Z. FDG-PET/CT for detecting relapse in patients with acute lymphoblastic leukemia. JPN J Clin Oncol. 2016;46(1):96-97. doi:10.1093/jjco/hvy196
37. Stolzel F, Rollig C, Radke J, et al. 18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia. Haematologica. 2011;96(10):1552-1556. doi:10.3324/haematol.2011.045047
38. Cunningham I, Kohno B. 18 FDG-PET/CT: 21st century approach to leukemic tumors in 124 cases. Am J Hematol. 2016;91(4):379-384. doi:10.1002/ajh.24287
39. Rao S, Langston A, Galt JR, Raghuveer KH. Extramedullary acute myeloid leukemia and the use of FDG-PET/CT. Clin Nucl Med. 2009;34(6):365-366. doi:10.1097/RLU.0b013e3181a3466d
40. Domas A, Skerget M, Zagar I. 18F-FDG PET/CT for staging and evaluation of therapy in a patient with unusual hairy cell leukemia presentation. Clin Nucl Med. 2019;44(7):e458-e460. doi:10.1097/RLU.0000000000002557
41. Matsui M, Yamanaka J, Shichino H, et al. FDG-PET/CT for detection of extramedullary disease in 2 pediatric patients with AML. J Pediatr Hematol Oncol. 2016;38(5):398-401. doi:10.1097/MPH.0000000000000447
42. Kayaz A, Akdemir OU, Atay OL, et al. Utility of 18-fluorodeoxyglucose positron emission tomography in children with relapsed/refractory leukemia. Pediatr Hematol Oncol. 2018;35(7-8):393-406. doi:10.1080/08880018.2018.1557306
43. Jain P, O’Brien S. Richter’s transformation in chronic lymphocytic leukemia. Oncology (Williston Park). 2012;26(12):1146-1152.
44. Shahi F, Janjua A, Van Gestel F, Ahmad A. Richter transformation of chronic lymphocytic leukemia: a review of fluorodeoxyglucose positron emission tomography-computed tomography and molecular diagnostics. Cureus. 2017;9(1):e968. doi:10.7759/cureus.968.
45. Robertson LE, Pugh W, O’Brien S, et al. Richter’s syndrome: a report on 39 patients. J Clin Oncol. 1993;11(10):1985-1989. doi:10.1200/JCO.1993.11.10.1985
46. Brecher M, Banks PM. Hodgkin’s disease variant of Richter’s syndrome. Report of eight cases. Am J Clin Pathol. 1990;93(3):333-339. doi:10.1093/ajcp/93.3.333
47. Litz CE, Arthur DC, Gajl-Peczalska KJ, et al. Transformation of chronic lymphocytic leukemia to small non-cleaved cell lymphoma: a cyogenetic, immunological, and molecular study. Leukemia. 1991;5(11):972-978.
48. Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol. 1928;4(4):285-292.
49. Tsimeridou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005;103(2):216-228. doi:10.1002/cncr.20773
50. Bekerman C, Hoffer PB, Bitran JD. The role of gallium-67 in the clinical evaluation of cancer. Semin Nucl Med. 1984;14(4):296-323. doi:10.1016/s0001-2998(84)80005-7
51. Partyka S, O’Brien S, Podoloff D, Kantarjian H, Keating MJ. The usefulness of high dose (7-10mci) gallium (67 Ga) scanning to diagnose Richter’s transformation. Leuk Lymphoma. 1999;36(1-2):151-155. doi:10.3109/10428199909145959
52. Mota PM, Dedes W, Yeoh SL, Soilleux E, Hague S. Ocular lymphoma with extrascleral extension as primary manifestation of Richter syndrome. Eye (Lond). 2012;26(6):891-893. doi:10.1038/eye.2012.41
53. Papajik T, Myslivecek M, Urbanova R, et al. 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation. Leuk Lymphoma. 2014;55(2):314-319. doi:10.3109/10428199909145959
54. Jerusalem G, Beguin Y, Najar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol. 2001;12(6):825-830. doi:10.1038/a1011169332265
55. Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006;47(8):1267-1273.
56. Michallet AS, Sesques P, Rabe KG, et al. An 18F-fluorodeoxyglucose maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter’s syndrome. Leuk Lymphoma. 2006;57(6):1474-1477. doi:10.1080/10428190500520263
tomography. Indian J Nucl Med. 2020;35(1):70-71. doi:10.4103/ijnm.IJNM175_19

58. Wang Y, Rabe KG, Bold MS, et al. The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukaemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica. 2020. doi:10.3324/haematol.2019.240564

59. Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990;75(4):1024-1030.

60. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406-414. doi:10.1182/blood.v100.2.406

61. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109(10):4119-4126. doi:10.1182/blood-2006-12-041889

62. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med. 2003;54:29-52. doi:10.1146/annurev.med.54.101601.152339

63. Martin PJ, McDonald GB, Sanders JE, et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2004;10(5):320-327. doi:10.1016/j.bbmt.2003.12.304

64. Harris AC, Ferrara JLM, Braun TM, et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012;119(12):2960-2963. doi:10.1182/blood-2011-10-387357

65. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol. 2001;29(3):259-277. doi:10.1016/s0301-472x(00)00677-9

66. Iqbal N, Salzman D, Lazenby AJ, Wilcox CM. Diagnosis of gastrointestinal graft-versus-host disease after allogeneic hematopoetic cell transplantation. Blood. 2011;117(1):140-143. doi:10.1182/blood-2010-11-307798

67. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15(6):825-828.

68. Stelljes M, Hermann S, Albring J, et al. Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography. Blood. 2008;111(5):2909-2918. doi:10.1182/blood-2007-10-119164

69. Bodet-Milin C, Lacombe M, Malard F, et al. 18F-FDG PET/CT for the assessment of gastrointestinal GVHD: results of a pilot study. Bone Marrow Transplant. 2014;49(1):131-137. doi:10.1038/bmt.2013.144

70. Dejanovic D, Amtoft A, Loft A. 18F-FDG PET/CT in extensive graft-versus-host disease of the gastrointestinal tract following autologous stem cell transplantation. Diagnostics (Basel). 2018;8(4):72. doi:10.3390/diagnostics8040072

71. Holter JL, Thorp K, Smith ML, et al. 18F-Fluorothymidine PET imaging in the diagnosis of leptomeningeal involvement with diffuse large B-cell lymphoma. Cancer Imaging. 2011;11(1):140-143. doi:10.1102/1470-7330.2011.0020

72. Herhaus P, Habringer S, Philipp-Abbrederis K, et al. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica. 2016;101(8):932-940. doi:10.3324/haematol.2016.142976

73. Mayerhöfer ME, Jaeger U, Staber P, et al. [68 Ga]-Pentixafor PET/MRI for CXCR4 imaging of chronic lymphocytic leukemia: preliminary results. Invest Radiol. 2018;53(7):403-408. doi:10.1097/RLI.0000000000000469

74. Giovacchini G, Fallanca F, Landoni C, et al. C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience. Clin Nucl Med. 2009;34(1):7-10. doi:10.1097/RLU.0b013e31818f4369

75. Qin C, Wu Z, Li J, Xun S, Xiaoli L. Differences in uptake of 18F-FDG and 11C-choline in a case of acute myeloid leukemia. Clin Nucl Med. 2016;41(10):799-801. doi:10.1097/RLU.0000000000001324

76. Cauchon N, Langlois R, Rousseau JA, et al. PET imaging of apoptosis with (64)Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V. Eur J Nucl Med Mol Imaging. 2007;34(2):247-258. doi:10.1007/s00259-006-0199-y

77. Faust A, Wagner S, Law MP, et al. The non peptidylcaspase binding radioligand (S)-1-(4-(2-[18F]Fluoroethoxy)-benzyl)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin ([18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Q J Nucl Med Mol Imaging. 2007;51(1):67-73.

78. Aloya R, Shirvan A, Grimberg H, et al. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis. 2006;11(12):2089-2101. doi:10.1007/s10495-006-0282-7